BriaCell Therapeutics Corp. (BCTX) Gains from Investment Securities (2021 - 2026)

BriaCell Therapeutics has reported Gains from Investment Securities for 6 years, with the latest figure at -$123242.0 in Q2 2026.

• Quarterly Gains from Investment Securities rose 29.91% year-over-year to -$123242.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$658158.0 (up 86.7% YoY) and the FY2025 annual result came in at -$758364.0, up 97.31% from the prior year.
• Gains from Investment Securities advanced to -$123242.0 in Q2 2026 per BCTX's latest filing, from -$211777.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $7.6 million in Q1 2023 and troughed at -$14.8 million in Q1 2022.
• A 5-year average of -$2.5 million and a median of -$465883.5 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities surged 151.56% in 2023, then plunged 1929.13% in 2024.
• Over 5 years, Gains from Investment Securities stood at -$4.1 million in 2022, then plunged by 246.84% to -$14.3 million in 2023, then soared by 104.32% to $616643.0 in 2024, then sank by 88.78% to $69201.0 in 2025, then tumbled by 278.09% to -$123242.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$123242.0, -$211777.0, and $69201.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.